Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Inflammatory Bowel Diseases

Free Subscription 29.09.2025 1 Aliment Pharmacol Ther 1 Clin Gastroenterol Hepatol 3 Dig Dis Sci 3 Gastroenterology 16 Inflamm Bowel Dis 2 J Clin Gastroenterol 10 J Crohns Colitis 1 J Gastroenterol 2 PLoS One 1 Proc Natl Acad Sci U S A 1 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. MASSIRONI S, Zilli A, Furfaro F, Allocca M, et al
   Systematic Review: Ultrasound Goes Echo-Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound.
   Aliment Pharmacol Ther. 2025 Sep 23. doi: 10.1111/apt.70385.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

2. LOVETT GC, Schulberg JD, Hamilton A, Wright EK, et al
   Long-term Results of Drug Treatment for Crohn's Disease Strictures.
   Clin Gastroenterol Hepatol. 2025 Sep 17:S1542-3565(25)00805.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

3. JAMAL F, Odeh NB, Alatout MHI, Khan MA, et al
   Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
   Dig Dis Sci. 2025 Sep 22. doi: 10.1007/s10620-025-09387.
   PubMed         Abstract available
   
   
4. BRONZE S, Shenoy S, Agrawal M, Polydorides AD, et al
   Prevalence and Clinical Features of Incidental Inflammatory Bowel Disease Identified During Screening and Surveillance Colonoscopy.
   Dig Dis Sci. 2025 Sep 19. doi: 10.1007/s10620-025-09400.
   PubMed         Abstract available
   
   
5. GORE E, Femino C, Aronskyy I, Miller A, et al
   The Patient Experience with Point-of-Care Intestinal Ultrasound for Inflammatory Bowel Disease Monitoring: A Multicenter Study.
   Dig Dis Sci. 2025 Sep 18. doi: 10.1007/s10620-025-09390.
   PubMed         Abstract available
   
   

   
   Gastroenterology

6. BOLTE LA, Bjork JR, Gacesa R, Weersma RK, et al
   Pharmacomicrobiomics: The Role of the Gut Microbiome in Immunomodulation and Cancer Therapy.
   Gastroenterology. 2025;169:813-827.
   PubMed         Abstract available
   
   
7. VAN LIEROP LMA, Devillers MJC, van der Woude CJ, Hoentjen F, et al
   Long-term outcomes of increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission: 3-year follow-up of the randomized controlled LADI trial.
   Gastroenterology. 2025 Sep 19:S0016-5085(25)06024.
   PubMed        
   
   
8. IRWIN S, van Daelen M, Almaraz I, Park R, et al
   Fidaxomicin Reduces Collagen Expression in Intestinal Fibroblasts Via Platelet-Derived Growth Factor Receptor Beta and Glycogen Synthase Kinase-3 Beta Inhibition.
   Gastroenterology. 2025;169:925-941.
   PubMed         Abstract available
   
   

   
   Inflamm Bowel Dis

9. STENKE E, Alhassan D, Moclair M, Cooper S, et al
   Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort-A Retrospective Study.
   Inflamm Bowel Dis. 2025;31:2331-2337.
   PubMed         Abstract available
   
   
10. AKASH H, Pandis N, Manschiebel W, Burisch J, et al
    A Systematic Review and Meta-Analysis of Animal Models on the Possible Link Between Periodontitis and Inflammatory Bowel Diseases.
    Inflamm Bowel Dis. 2025;31:2561-2583.
    PubMed         Abstract available
    
    
11. VERMEER E, Prins FM, Hidding IJ, Jagt JZ, et al
    Metagenomic Sequencing Reveals Distinct Gut Microbiome Profiles in Therapy-Naive de Novo Pediatric Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2025 Sep 12:izaf184. doi: 10.1093.
    PubMed         Abstract available
    
    
12. JAIRATH V, Adsul S, Allocca M, Danese S, et al
    Integrating Intestinal Ultrasound to Clinical Trials in Patients With Crohn's Disease: Opportunities and Challenges.
    Inflamm Bowel Dis. 2025 Sep 15:izaf196. doi: 10.1093.
    PubMed         Abstract available
    
    
13. FROST S, Ambastha C, Patel D, Roney A, et al
    Incidence of Anti-Drug Antibody Development in Older Adults with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Inhibitors: A Large Multicenter Cohort Study.
    Inflamm Bowel Dis. 2025 Sep 15:izaf170. doi: 10.1093.
    PubMed         Abstract available
    
    
14. CHEN Q, McNinch C, May E, LaPoint P, et al
    Distinct Retrotransposon Transcriptome in Pediatric Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 15:izaf190. doi: 10.1093.
    PubMed         Abstract available
    
    
15. SCHREIBER S, Lee SD, van der Woude CJ, Marin-Jimenez I, et al
    Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease.
    Inflamm Bowel Dis. 2025 Sep 15:izaf163. doi: 10.1093.
    PubMed         Abstract available
    
    
16. FUCHTBAUER JD, Brovkina O, Sivickis K, Aalykke C, et al
    Gut Mycobiome in Inflammatory Bowel Disease: A Systematic Review of Case-Control Studies.
    Inflamm Bowel Dis. 2025 Sep 24:izaf217. doi: 10.1093.
    PubMed         Abstract available
    
    
17. TEIGEN L
    Deciphering Mechanisms Underlying Success of Microbiome-Targeted Diet Therapy in Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 23:izaf203. doi: 10.1093.
    PubMed        
    
    
18. INNOCENTI T, Rocco C, Scarallo L, Lionetti P, et al
    Systematic Review of Available Intestinal Ultrasound Scores for Inflammatory Bowel Disease and Update on Validation Studies.
    Inflamm Bowel Dis. 2025 Sep 20:izaf183. doi: 10.1093.
    PubMed         Abstract available
    
    
19. SINOPOULOU V, Gordon M, Liu S, Albuquerque DAN, et al
    Immunomodulators and Advanced Therapies for Induction of Remission in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2025 Sep 19:izaf191. doi: 10.1093.
    PubMed         Abstract available
    
    
20. BAEKGAARD FRW, Kjaer MD, Moller S, Hovvang SW, et al
    The Severity of Rectal Inflammation and Pouch Surgery Outcome in Patients with Ulcerative Colitis: A Retrospective Cohort Study.
    Inflamm Bowel Dis. 2025 Sep 16:izaf194. doi: 10.1093.
    PubMed         Abstract available
    
    
21. SHEHAB M, Alrashed O, Alrashed F, Alyousefi R, et al
    Comparative Efficacy of Medical Therapies in Reducing the Risk of Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Inflamm Bowel Dis. 2025 Sep 18:izaf186. doi: 10.1093.
    PubMed         Abstract available
    
    
22. TAN EX, An V, Garg M
    Diverting Loop Ileostomy as an Alternative to Emergent Colectomy in Acute Severe Ulcerative Colitis Flare following Checkpoint-Inhibitor Therapy.
    Inflamm Bowel Dis. 2025 Sep 19:izaf187. doi: 10.1093.
    PubMed        
    
    
23. OH SH, Rajendra C
    Capsule Endoscopy in Very Early-Onset Inflammatory Bowel Disease: Supporting the Clinician's Role in Disease Interpretation.
    Inflamm Bowel Dis. 2025 Sep 18:izaf165. doi: 10.1093.
    PubMed        
    
    
24. DRUGG HAHN G, Lakatos PL, Maedler-Kron C, Marcus V, et al
    Defining Fecal Calprotectin Cutoffs That Predict Endoscopic and Histologic Remission in Patients With Ulcerative Colitis.
    Inflamm Bowel Dis. 2025 Sep 19:izaf008. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

25. TANRIVERDI LH, Aksan F, Aroniadis O, Monzur F, et al
    S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis: A Stratified Meta-Analysis By Prior Biological Use, Corticosteroid Exposure, and Disease Characteristics.
    J Clin Gastroenterol. 2025 Sep 23. doi: 10.1097/MCG.0000000000002250.
    PubMed         Abstract available
    
    
26. NARDELLI MJ, Cancado GGL, Barros LL, Dotta DD, et al
    Clinical and Prognostic Factors Associated With Inflammatory Bowel Disease in a Highly Admixed Population With Primary Sclerosing Cholangitis.
    J Clin Gastroenterol. 2025 Sep 24. doi: 10.1097/MCG.0000000000002253.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

27. FAGGIANI I, Bencardino S, Peyrin-Biroulet L
    Catching fibrosis in motion: time-dependent diffusion MRI-derived cell diameter reveals the transitional state of intestinal scarring in Crohn's disease.
    J Crohns Colitis. 2025;19:jjaf146.
    PubMed        
    
    
28. 
    Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study.
    J Crohns Colitis. 2025;19:jjaf123.
    PubMed        
    
    
29. BRAND EC, Roosenboom B, Lutter L, Malvar Fernandez B, et al
    Mucosal Kinase Activity and Inflammatory Profiles in Inflammatory Bowel Disease, and in Relation with Tofacitinib Response.
    J Crohns Colitis. 2025 Sep 23:jjaf174. doi: 10.1093.
    PubMed         Abstract available
    
    
30. HILLEY P, Chin S, Wong D, De Cruz P, et al
    Implementation of Values based healthcare in inflammatory bowel disease-a review article.
    J Crohns Colitis. 2025 Sep 19:jjaf173. doi: 10.1093.
    PubMed         Abstract available
    
    
31. COLWILL M, Povlsen S, Pollok R, Patel K, et al
    Glucagon-Like Peptide (GLP-1) Receptor Agonists in Inflammatory Bowel Disease: Mechanisms, Clinical Implications, and Therapeutic Potential.
    J Crohns Colitis. 2025 Sep 16:jjaf167. doi: 10.1093.
    PubMed         Abstract available
    
    
32. ROTEM-TRYFUS O, Kang B, Orlanski-Meyer E, Ledder O, et al
    Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study.
    J Crohns Colitis. 2025 Sep 19:jjaf172. doi: 10.1093.
    PubMed         Abstract available
    
    
33. LEGA S, Dipasquale V, D'arcangelo G, Scarallo L, et al
    Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.
    J Crohns Colitis. 2025 Sep 19:jjaf164. doi: 10.1093.
    PubMed         Abstract available
    
    
34. MASSIMINO L, Solitano V, Ungaro F
    Repurposing losartan for fibrostenosing Crohn's disease: a compelling preclinical rationale.
    J Crohns Colitis. 2025;19:jjaf147.
    PubMed        
    
    
35. RAJA SS, Costello SP, Rayner CK, Day A, et al
    Examining the role of faecal microbiota transplantation for inducing remission in resistant ulcerative proctitis and distal ulcerative colitis (up-FMT).
    J Crohns Colitis. 2025 Sep 18:jjaf169. doi: 10.1093.
    PubMed         Abstract available
    
    
36. ALLOCCA M, Jairath V, Sands BE, Rubin DT, et al
    International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
    J Crohns Colitis. 2025 Sep 18:jjaf170. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

37. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2025 Sep 22. doi: 10.1007/s00535-025-02299.
    PubMed         Abstract available
    
    

    
    PLoS One

38. CAI B, Qin X, Huang X, He X, et al
    Molecular mechanisms of dragon's blood in treating ulcerative colitis based on NF-kappab/NLPR3/Caspase-1 pyroptosis signaling pathway.
    PLoS One. 2025;20:e0331570.
    PubMed         Abstract available
    
    
39. XIA P, Deng F, Liu D
    Development and validation of a machine learning-based predictive model for clinical remission in Crohn's disease patients receiving Adalimumab therapy.
    PLoS One. 2025;20:e0331447.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

40. CHEN X, Hwang HS, Li B, Zhao Y, et al
    Nuclear receptor coregulator NRIP1 R448G modulates T cell gut homing to control intestinal inflammation.
    Proc Natl Acad Sci U S A. 2025;122:e2508269122.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

41. YE C, Li W, Li X, Jiang Q, et al
    Risk factors for mucosal cytomegalovirus infection and specific endoscopic features in patients with ulcerative colitis.
    Scand J Gastroenterol. 2025 Sep 19:1-11. doi: 10.1080/00365521.2025.2558970.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.